J&J to acquire remainder of Crucell
NEW BRUNSWICK, N.J. Johnson & Johnson is set to buy up the remaining portion of Dutch biotech company Crucell that it doesn’t already own, J&J said Friday.
The drug maker said the two companies were in “advanced negotiations” for J&J to buy up the remainder of Crucell for around $2.3 billion. J&J currently owns slightly less than 18% of the company through an affiliate.
J&J said it would benefit from Crucell’s expertise in vaccines and gain a “strong platform” in the vaccine market. The drug maker said it plans to keep Crucell as the center for vaccines in the conglomerate and maintain its headquarters in Leiden, Netherlands.
Caraco adds new member to board
DETROIT Caraco Pharmaceutical Labs has appointed a new member to its board of directors.
The generic drug maker announced Wednesday the appointment of former KPMG accountant Eddie Munson to its board of directors.
Munson, who served in various positions for KPMG, will serve on Caraco’s board of directors for a term ending at the 2011 annual meeting of shareholders.
Novo Nordisk featured in Working Mother’s ‘100 Best Companies’ list
PRINCETON, N.J. Working Mother magazine has named drug maker Novo Nordisk one of the best companies in the country for family-friendly benefits, the company said Thursday.
The U.S. subsidiary of the Danish drug maker was named a Working Mother 100 Best Company for programs designed to help families balance work-life needs, such as adoption reimbursement, health benefits, paid time off and assistance for families sending their kids to college.
“It is an honor to be named as a Working Mother 100 Best Company,” said Novo Nordisk VP human resources Jeff Frazier. “This recognition shows our commitment to supporting a diverse and inclusive work environment, where everyone has an opportunity to participate in creating business success and people are valued for their unique skills, experiences and perspectives.”